ALNY - ALNYLAM PHARMACEUTICALS, INC.
IEX Last Trade
241.805
0.055 0.023%
Share volume: 9,065
Last Updated: Thu 26 Dec 2024 08:29:33 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$241.75
0.06
0.02%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-10-27 | 2023-02-23 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-02-15 | 2024-05-02 | 2024-08-01 | |
| Total revenue | 264.306 M | 335.035 M | 319.290 M | 318.754 M | 750.530 M | 439.718 M | 494.333 M | 659.825 M | |
| Cost of revenue | 41.116 M | 51.266 M | 54.869 M | 85.370 M | 84.309 M | 85.858 M | 65.976 M | 68.672 M | |
| Gross profit | 223.190 M | 283.769 M | 264.421 M | 233.384 M | 666.221 M | 353.860 M | 428.357 M | 591.153 M | |
| 27.14% | -6.82% | -11.74% | 185.46% | -46.89% | 21.05% | 38.00% | |||
| Operating expenses | 481.230 M | 472.383 M | 414.228 M | 463.215 M | 452.354 M | 470.264 M | 471.792 M | 542.539 M | |
| Selling general and admin | 235.859 M | 210.344 M | 183.659 M | 214.689 M | 199.175 M | 198.123 M | 210.797 M | 248.397 M | |
| Research and development | 245.371 M | 262.039 M | 230.569 M | 248.526 M | 253.179 M | 272.141 M | 260.995 M | 294.142 M | |
| Total expenses | 522.346 M | 523.649 M | 469.097 M | 548.585 M | 536.663 M | 556.122 M | 537.768 M | 611.211 M | |
| 0.25% | -10.42% | 16.94% | -2.17% | 3.63% | -3.30% | 13.66% | |||
| Operating income | -258.040 M | -188.614 M | -149.807 M | -229.831 M | 213.867 M | -116.404 M | -43.435 M | 48.614 M | |
| Ebit | -258.040 M | -188.614 M | -149.807 M | -229.831 M | 213.867 M | -116.404 M | -43.435 M | 48.614 M | |
| Pretax income | -405.943 M | -207.021 M | -172.362 M | -274.209 M | 150.741 M | -137.687 M | -63.587 M | -11.167 M | |
| -49.00% | -16.74% | 59.09% | -154.97% | -191.34% | -53.82% | -82.44% | |||
| Income tax | -23.000 K | 472.000 K | 1.739 M | 1.815 M | 2.988 M | 183.000 K | 2.348 M | 5.722 M | |
| Net income basic | -405.920 M | -207.493 M | -174.101 M | -276.024 M | 147.753 M | -137.870 M | -65.935 M | -16.889 M | |
| 48.88% | 16.09% | -58.54% | 153.53% | -193.31% | 52.18% | 74.39% | |||
| Net income | -405.920 M | -207.493 M | -174.101 M | -276.024 M | 147.753 M | -137.870 M | -65.935 M | -16.889 M | |
| 48.88% | 16.09% | -58.54% | 153.53% | -193.31% | 52.18% | 74.39% |